Table 1.

Sample sizes

Groups (deduped)*	Sample size (n)
All oral bitherapy or tritherapy users	443
Uncontrolled** bitherapy or tritherapy users	105
without any complications	360
All insulin users	270
With:
Early insulin initiation (5 years or less)	143
Early insulin initiation (5 years or less) without any complication^	77
Short duration of insulin (5 years or less)	141
Short duration of insulin (5 years or less) without any complication^	94

Notes:

^*Users of glucagon-like peptide-1 were excluded from this analysis due to their small sample size (n = 46)

^**uncontrolled users were defined as having an HbA_1c >7% or, if they were missing their HbA_1c level their fasting plasma glucose was >130 mg/dL; ^a complication was defined as reporting having myocardial infarction, stroke, transient ischemic attack, diabetic retinopathy, diabetic peripheral neuropathy, kidney damage, end organ damage (only collected in 2010 and 2011), or foot ulcer.